Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Daniel M. Togasaki, MD, PhD

    TitleAssociate Professor of Clinical Neurology
    SchoolKeck School of Medicine of USC
    DepartmentNeurology
    AddressHCT 3000
    Health Sciences Campus
    Los Angeles California 90089
    Phone+1 323 442 5728
    vCardDownload vCard

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Berkovich R, Togasaki D, Cen SY, Steinman L. CD4 cell response to interval therapy with natalizumab. Ann Clin Transl Neurol. 2015 May; 2(5):570-4. PMID: 26000328; PMCID: PMC4435710.
      2. Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb; 71(2):141-50. PMID: 24366103; PMCID: PMC3940333.
      3. Factor SA, Wolski K, Togasaki D, Huyck S, Cantillon M, Ho TW, Hauser RA, Pourcher E. Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease. Mov Disord. 2013 Jun; 28(6):817-20. PMID: 23589371.
        View in: PubMed
      4. Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA. Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord. 2013 Mar; 28(3):380-3. PMID: 23339054; PMCID: PMC3608707.
      5. Vuckovic MG, Wood RI, Holschneider DP, Abernathy A, Togasaki D, Smith A, Petzinger GM, Jakowec MW. Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol Dis. 2008 Nov; 32(2):319-27. PMID: 18718537; PMCID: PMC3280725.
      6. Petzinger GM, Walsh JP, Akopian G, Hogg E, Abernathy A, Arevalo P, Turnquist P, Vuckovic M, Fisher BE, Togasaki D, Jakowec MW. Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J Neurosci. 2007 May 16; 27(20):5291-300. PMID: 17507552.
        View in: PubMed
      7. Cox H, Togasaki D, Chen L, Langston JW, Di Monte DA, Quik M. The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates. Exp Neurol. 2007 May; 205(1):101-7. PMID: 17335811; PMCID: PMC2001245.
      8. Togasaki D, Hsu A, Samant M, Farzan B, DeLanney LE, Langston JW, Di Monte DA, Quik M. The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates. J Neurosci Methods. 2005 Jun 30; 145(1-2):159-66. PMID: 15922034.
        View in: PubMed
      9. Togasaki D, Protell P, Tan LC, Langston JW, Di Monte DA, Quik M. Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa. Neuropharmacology. 2005 Mar; 48(3):398-405. PMID: 15721172.
        View in: PubMed
      10. Chen L, Togasaki D, Langston JW, Di Monte DA, Quik M. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys. Neuroscience. 2005; 132(2):409-20. PMID: 15802193.
        View in: PubMed
      11. Hsu A, Togasaki D, Bezard E, Sokoloff P, Langston JW, Di Monte DA, Quik M. Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. J Pharmacol Exp Ther. 2004 Nov; 311(2):770-7. PMID: 15226382.
        View in: PubMed
      12. Tan LC, Protell PH, Langston JW, Togasaki D. The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys. Mov Disord. 2002 Sep; 17(5):902-9. PMID: 12360538.
        View in: PubMed
      13. Yee RE, Huang SC, Togasaki D, Langston JW, Satyamurthy N, Barrio JR. Imaging and therapeutics: the role of neuronal transport in the regional specificity of L-DOPA accumulation in brain. Mol Imaging Biol. 2002 May; 4(3):208-18. PMID: 14537125.
        View in: PubMed
      14. Yee RE, Irwin I, Milonas C, Stout DB, Huang SC, Shoghi-Jadid K, Satyamurthy N, Delanney LE, Togasaki D, Farahani KF, Delfani K, Janson AM, Phelps ME, Langston JW, Barrio JR. Novel observations with FDOPA-PET imaging after early nigrostriatal damage. Mov Disord. 2001 Sep; 16(5):838-48. PMID: 11746613.
        View in: PubMed
      15. Togasaki D, Tan L, Protell P, Di Monte DA, Quik M, Langston JW. Levodopa induces dyskinesias in normal squirrel monkeys. Ann Neurol. 2001 Aug; 50(2):254-7. PMID: 11506410.
        View in: PubMed
      16. Togasaki D, Tanner CM. Epidemiologic aspects. Adv Neurol. 2000; 82:53-9. PMID: 10624470.
        View in: PubMed
      17. Mena MA, Khan U, Togasaki D, Sulzer D, Epstein CJ, Przedborski S. Effects of wild-type and mutated copper/zinc superoxide dismutase on neuronal survival and L-DOPA-induced toxicity in postnatal midbrain culture. J Neurochem. 1997 Jul; 69(1):21-33. PMID: 9202290.
        View in: PubMed
      18. Dethy S, Laute MA, Togasaki D, Przedborski S, Damhaut P, Thiry P, Hildebrand J, Goldman S. Systemic and intrastriatal theophylline have opposite effects on dopamine and dopamine metabolites measured by intrastriatal microdialysis in the rat. Neurosci Lett. 1996 Apr 26; 208(3):159-62. PMID: 8733294.
        View in: PubMed
      19. Parsons B, Togasaki D, Kassir S, Przedborski S. Neuroleptics up-regulate adenosine A2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia. J Neurochem. 1995 Nov; 65(5):2057-64. PMID: 7595490.
        View in: PubMed
      20. Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D, Togasaki D. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience. 1995 Aug; 67(3):631-47. PMID: 7675192.
        View in: PubMed
      21. Levivier M, Holemans S, Togasaki D, Maloteaux JM, Brotchi J, Przedborski S. Quantitative assessment of quinolinic acid-induced striatal toxicity in rats using radioligand binding assays. Neurol Res. 1994 Jun; 16(3):194-200. PMID: 7936089.
        View in: PubMed
      22. Togasaki D, Young JG, Knott PJ. L-dihydroxyphenylalanine-induced asymmetric changes in striatal uric acid peak: determination by in vivo electrochemical detection in rats with unilateral nigrostriatal lesions. Life Sci. 1987 Sep 14; 41(11):1361-7. PMID: 3114581.
        View in: PubMed
      23. Brannan T, Weinberger J, Knott P, Taff I, Kaufmann H, Togasaki D, Nieves-Rosa J, Maker H. Direct evidence of acute, massive striatal dopamine release in gerbils with unilateral strokes. Stroke. 1987 Jan-Feb; 18(1):108-10. PMID: 3810742.
        View in: PubMed
      24. Arnold MA, Carr DB, Togasaki D, Pian MC, Martin JB. Caffeine stimulates beta-endorphin release in blood but not in cerebrospinal fluid. Life Sci. 1982 Sep 06; 31(10):1017-24. PMID: 6290811.
        View in: PubMed